![Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9a8d6f8d-8b85-45e3-a86b-0658775b46bd/gr1_lrg.jpg)
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology
Long-term survival in the patient with generalized HER-2 positive, hormone-independent breast cancer - the importance of a multi
![Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/03ea64b3-8bc1-4956-a1fb-634144317b3c/gr1.jpg)
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology
![Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - ScienceDirect Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753412X47008-cov150h.gif)